Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

The Journal of Infectious Diseases(2025)10.1093/infdis/jiaf176Source: DataRank Database

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine is a research paper published in The Journal of Infectious Diseases (2025). On theSindex it has a DataRank of 0.284. It has been cited 4 times, with 3 citing works in its 1-hop citation network.

N/A

0.284DataRank · unranked

Scored on demand from live citation data

Deposits data4 citations · 3 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT04889209

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (22 grants)Impact (FWCI 3.11)OA: closedTopics (64)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 85%Citation Network 15%

Base Score Contribution

0.241

From this paper's citation signal

Citation Network Contribution

0.0424

From 1 citing papers with measurable signal

Learn more about DataRank methodology →

Top 3 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 3 citers.

Early rise in nasal secretory IgA associated with shorter duration of SARS-CoV-2 virus shedding in an acute infection cohort
Frontiers in Immunology20262 citations22 referencesContributes 0.050
Comment on: “Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine”
The Journal of Infectious Diseases20260 citations10 referencesContributes 0.000
Anti-SARS-CoV-2 response in alveolar blood sample and bronchoalveolar lavage fluid of individuals vaccinated with inactivated COVID-19 vaccines
Human Vaccines & Immunotherapeutics20260 citations35 referencesContributes 0.000

Authors (37)

Kirsten E. Lyke ORCID,Christine M. Posavad ORCID,Meagan E. Deming ORCID,Rebecca C. Brady ORCID,David Dobrzynski ORCID

Live enrichment

PubMed:40298376 PMC:PMC12526981 OpenAlex:https://openalex.org/W4409926911

National Institutes of Health

Grant: UM1AI48372

National Institutes of Health

Grant: UM1AI148373

National Institutes of Health

Grant: UM1AI148450

National Institutes of Health

Grant: UM1AI148452

National Institutes of Health

Grant: UM1AI148573

National Institutes of Health

Grant: UM1AI148574

National Institutes of Health

Grant: UM1AI148575

National Institutes of Health

Grant: UM1AI148576

National Institutes of Health

Grant: UM1AI148684

National Institutes of Health

Grant: UM1 AI148689)

NIAID Collaborative Influenza Vaccine Innovation Centers

Grant: 75N93019C00050)

NIAID NIH HHS

Grant: UM1 AI148689

NIAID NIH HHS

Grant: 75N93019C00050

NIAID NIH HHS

Grant: UM1 AI148372

National Institute of Allergy and Infectious Diseases

Vaccine Research Center

National Institutes of Health Vaccine Research Center

Infectious Diseases Clinical Research Consortium

National Institutes of Health Vaccine Research Center

Infectious Diseases Clinical Research Consortium

National Institute of Allergy and Infectious Diseases

Vaccine Research Center

FWCI

3.11

Citation Percentile

0.9%

Citation Trend

2025

2026

closedLicense: public-domain

publisherhttps://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiaf176/63011307/jiaf176.pdf

publisherhttps://academic.oup.com/jid/article-pdf/232/4/971/63011307/jiaf176.pdf

journalhttps://doi.org/10.1093/infdis/jiaf176

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40298376

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/12526981

Fields of Study

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesCOVID-19 Clinical Research StudiesMedicineHumansMaleFemaleAdultAntibodies, ViralSARS-CoV-2COVID-19Immunization, SecondaryMiddle AgedCOVID-19 VaccinesImmunity, Mucosal2019-nCoV Vaccine mRNA-1273Young AdultAntibodies, NeutralizingAdolescentImmunoglobulin GImmunoglobulin AAntibody Formation

MeSH Terms

COVID-19SARS-CoV-2COVID-19 Vaccines2019-nCoV Vaccine mRNA-1273AdolescentAdultAntibodies, ViralAntibody FormationFemaleHumansImmunoglobulin AImmunoglobulin GImmunization, SecondaryMaleMiddle AgedImmunity, MucosalYoung AdultAntibodies, Neutralizing

Keywords

MedicineImmunologyImmunogenicityAntibodyBooster doseCoronavirusNorovirusVaccinationImmunityAdverse effectImmunoglobulin AImmune systemVirologyTiterImmunoglobulin GVirusInternal medicineDiseaseCoronavirus disease 2019 (COVID-19)Infectious disease (medical specialty)VaccineBoosterCovid-19Sars-cov-2

Sustainable Development Goals

SDG 0: Good health and well-being

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

FAIR Checklist

DataRank Breakdown

Top 3 citers driving the network score

Authors (37)

Funding (22 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)